Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity

Table 3 Impacts of lnAUC_gla on overall peripheral nerve function by multivariable linear regression analysis in the T2D/OB group (n = 174)

Models	B (95% CI)	β	t	p	R²
Overall composite Z-score for latency
Model 0	−0.281 (−0.424, −0.138)	−0.283	−3.875	< 0.001	0.080
Model 1	−0.248 (−0.388, −0.108)	−0.251	−3.505	0.001	0.296
Model 2	−0.285 (−0.471, −0.099)	−0.266	−3.055	0.003	0.407
Model 3	−0.326 (−0.516, −0.136)	−0.304	−3.391	0.001	0.443
Overall composite Z-score for amplitude
Model 0	0.289 (0.148, 0.430)	0.295	4.043	< 0.001	0.087
Model 1	0.162 (0.037, 0.288)	0.166	2.548	0.012	0.418
Model 2	0.210 (0.006, 0.414)	0.202	2.040	0.044	0.473
Model 3	0.265 (0.065, 0.466)	0.256	2.630	0.010	0.550
Overall composite Z-score for NCV
Model 0	0.389 (0.238, 0.539)	0.362	5.096	< 0.001	0.131
Model 1	0.263 (0.120, 0.405)	0.245	3.640	< 0.001	0.376
Model 2	0.276 (0.094, 0.458)	0.242	3.001	0.003	0.498
Model 3	0.325 (0.141, 0.509)	0.286	3.503	0.001	0.541

Model 0: unadjusted
Model 1: adjusted for age, sex, diabetes duration, BMI, SBP, DBP, hypertension and statin treatment
Model 2: additionally adjusted for ALT, albumin, TG, TC, UA, CysC, eGFR, ACR, C-peptide, hemoglobin, glycated albumin, and HbA1c
Model 3: additionally adjusted for hypoglycemic agents
lnAUC_gla natural log-transformed AUC_gla, T2D type 2 diabetes, T2D/OB patients with T2D and obesity, NCV nerve conduction velocity

ISSN: 1758-5996